Roche: FDA approves new leukaemia treatment
(CercleFinance.com) - The US Food and Drug Administration has approved Roche and AbbVie's new treatment for leukaemia.
The FDA has approved Venclexta, in combination with Gazyva, for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), the companies said.
Venclexta has been designed to inhibit the B-cell lymphoma-2, which builds up and prevents cancer cells from dying or self-destructing.
Venclexta is being jointly developed by AbbVie and Roche. It is commercialised by AbbVie and Roche's Genentech in the US and marketed by AbbVie elsewhere.
Yesterday Roche announced positive data from a Phase I/II study, evaluating the investigational medicine entrectinib in children and teenagers with recurrent or refractory solid tumours.
Copyright (c) 2019 CercleFinance.com. All rights reserved.